Five-year results of the treatment of 23 patients with immunoproliferative small intestinal disease: a Turkish experience.

Abstract

BACKGROUND:

Currently, there is no agreement regarding optimal treatment strategies for immunoproliferative small intestinal disease (IPSID). In this article, the authors report the treatment outcomes of a group of 23 Turkish patients with IPSID.

METHODS:

Between December 1988 and July 1993, 23 consecutive patients with IPSID, including 5 with secretory type, were included in the study. Seven patients with Stage A disease (according to the criteria of Galien et al.) received tetracycline (1 g/day, orally) for a median duration of 7 months (range, 6-11 months) initially, whereas the remaining patients (9 Stage B patients and 7 Stage C patients) received combination chemotherapy (cyclophosphamide, vincristine, procarbazine, and prednisolone [COPP regimen]) followed by tetracycline at a dose of 1 g/day for 6 more months in patients with complete response (CR) after the COPP regimen.

RESULTS:

The median follow-up was 68 months (range, 38-89 months). As first-line therapy in Stage A patients, tetracycline yielded a 71% CR and 43% disease free survival (DFS) rate. Eleven of 16 patients (69%) with Stage B or C disease who received the COPP regimen achieved CR and only 2 patients had a recurrence (DFS rate of 56%). The 5-year overall survival (OAS) rate for the entire group was 70%, and the 5-year DFS rate for patients with CR was 75%. However, the median OAS for 3 patients with immunoblastic lymphoma was only 7 months.

CONCLUSIONS:

The COPP regimen, with its acceptable toxicity, appears to be a good alternative as a first-line treatment for patients with Stage B or C IPSID with low grade lymphoma whereas tetracycline appears to be the initial treatment of choice for patients with Stage A disease.

• Authors: H Akbulut, I Soykan, F Yakaryilmaz, F Icii, F Aksoy, S Haznedaroglu, S Yildirim
• Journal: Cancer (Cancer) Vol. 80 Issue 1 Pg. 8-14 (Jul 01 1997) ISSN: 0008-543X [Print] United States
• PMID: 9210703 (Publication Type: Clinical Trial, Journal Article, Review)

Chemical References

• Anti-Bacterial Agents
• Procarbazine
• Vincristine
• Doxorubicin
• Cyclophosphamide
• Tetracycline
• Prednisone

Topics

• Adolescent
• Adult
• Anti-Bacterial Agents (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Child
• Cyclophosphamide (administration & dosage)
• Disease-Free Survival
• Doxorubicin (administration & dosage)
• Female
• Humans
• Immunoproliferative Small Intestinal Disease (drug therapy, pathology)
• Intestine, Small (pathology)
• Male
• Prednisone (administration & dosage)
• Procarbazine (administration & dosage)
• Tetracycline (administration & dosage)
• Treatment Outcome
• Turkey
• Vincristine (administration & dosage)